Gastric Cancer Treatment Market, By Treatment (Surgery, Chemo Therapy, Adjuvant Chemotherapy, Targeted Drugs Therapy (Sunitinib (Sutent), Trastuzumab (Herceptin), and Imatinib (Gleevec)), and Radiation Therapy), By End-User (Hospitals, Clinics, Specialized Cancer Treatment Centers, and Ambulatory Surgical Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa - Trends, Analysis and Forecast till 2034

 

Gastric Cancer Treatment Market was valued at US$ 5.4 Billion in 2024 and is projected to grow at a CAGR of 13.7% to reach US$ 19.4 Billion by 2034.

[PDF] Gastric cancer is also known as stomach cancer which deals with the growth of cancerous cells within the lining of the stomach. Different type of cancers that spread in different type of cells are seen for example Adenocarcinoma in mucus-producing cells, Gastroesophageal junction adenocarcinoma in area where esophagus meets gastric cardia, gastrointestinal neuroendocrine tumors in neuroendocrine cells.

The global increase in stomach cancer cases is anticipated to fuel the growth of the gastric cancer treatment market. Additionally, it is projected that the incidence of stomach cancer will continue to rise in the next years, and this trend is increasing the demand for efficient therapies. The intake of highly processed foods, sugary beverages, smoking, genetic mutation of genes, family history of cancer, and alcohol have increased the causes of stomach cancer. A sedentary lifestyle and irregular eating habits are contributing to catastrophic diseases like Gastric Cancer

Growing approvals of drugs in new treatment method

Treatment method such as targeted therapy and immunotherapy drug are gaining popularity worldwide, for example Targeted drugs such as Herceptin and Cyramza are frequently used for treating gastric cancer in developed countries such as the U.S. growing approvals of new drugs with new offering which can help in market expansion and eventually result in Gastric Cancer Market growth.

For instance, in April 2021, according to Food and Drugs Administration, nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-containing chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma has been approved. A randomized, multicenter, open-label trial that enrolled 1,581 patients with previously untreated advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma was done, in which number of patients received nivolumab in combination with chemotherapy (n=789) and chemotherapy alone (n=792).

Rise in government spending on healthcare

Through recent years a significant rise in government spending on healthcare has been observed worldwide, this can boost the Gastric Cancer Treatment Market growth. Establishing new research and development labs which will help in technological advancement in current technology and also introducing a new treatment method which will eventually result in target market expansion. Also, increasing the number of qualities of medical infrastructure helps in early diagnosis or identification of Gastric Cancer.  

For instance, in FY (Fiscal Year) 2023, according to National Cancer Institute, NCI receives its budget of $7.3 billion from the United States Congress as part of the federal budget process through appropriations for the Department of Health and Human Services and NIH. The budget was a $408 million increase over the FY 2022 enacted level, included $216 million for the NCI component of the Cancer Moonshot.

Restrains:

Launch of biosimilars

Launch and approvals of biosimilars can restrain the target market growth as they come with lesser price as compared with branded drugs because since they are very identical copies of their reference biologics and have equal efficacy and safety, biosimilar pharmaceuticals require a lot less research and development than their reference biologics. Because of same price and same efficacy some section of population may choose biosimilars over branded drugs.

Furthermore, March 2022, according to the Oncology Nursing News, The FDA has approved a proposed biologics licence application (BLA) for a trastuzumab (Herceptin) biosimilar. The procedure has been suggested as an adjuvant therapy for HER2-overexpressing metastatic breast cancer, HER2-overexpressing gastric or gastroesophageal junction adenocarcinoma

Gastric Cancer Treatment Market is segmented based on Treatment, End-Users and Region.

Treatment Insight

On the basis of Treatment, Gastric Cancer Treatment Market is segmented into Surgery, Chemo Therapy, Adjuvant Chemotherapy, Targeted Drugs Therapy (Sunitinib (Sutent), Trastuzumab (Herceptin), and Imatinib (Gleevec)), and Radiation Therapy. Chemotherapy segment is expected to dominate the target market growth as in severe cases of gastric cancer, chemotherapy can be used to target cancer cells that have spread outside of the stomach, to reduce the tumor before surgery, and to relieve symptoms.

End User Insights

On the basis of End User, Gastric Cancer Treatment Market is segmented Hospitals, Clinics, Specialized Cancer Treatment Centers, and Ambulatory Surgical Centers.  Specialized cancer treatment Centre are expected to dominate the target market growth as they have latest available drugs, technology and proper manpower to handle, diagnose and treat patients. 

Regional Insights:

On the basis of region, the Gastric Cancer Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Europe market is estimated to witness a significantly high revenue share over the forecast period, due to good medical infrastructure and increasing elderly population which are anticipated to increase demand for gastric Cancer treatment in the region.

Report Scope:

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 – 2034
Market Segmentation	By Treatment - Surgery, Chemo Therapy, Adjuvant Chemotherapy, Targeted Drugs Therapy (Sunitinib (Sutent), Trastuzumab (Herceptin), and Imatinib (Gleevec)), and Radiation Therapy By End User - Hospitals, Clinics, Specialized Cancer Treatment Centers, and Ambulatory Surgical Centers
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 – 2034. For the purpose of this study, has segmented the Gastric Cancer Treatment Market report based on Treatment, End-Users and Region:

Gastric Cancer Treatment Market, By Treatment:

• Surgery
• Chemo Therapy
• Adjuvant Chemotherapy
• Targeted Drugs Therapy (Sunitinib (Sutent), Trastuzumab (Herceptin), Imatinib (Gleevec))
• Radiation Therapy

Gastric Cancer Treatment Market, By End-Users:

• Hospitals
• Clinics
• Specialized Cancer Treatment Centers
• Ambulatory Surgical Centers

Gastric Cancer Treatment Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

Recent Development:

• In April 2021, For the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, the FDA has approved “Opdivo” in combination with specific forms of chemotherapy. This is the first immunotherapy for gastric cancer that the FDA has approved.
• In January 2021 The US Food and Drug Administration has given the drug "Enhertu" by “AstraZeneca” and “Daiichi Sankyo Company”, Limited approval for the treatment of adult patients with locally progressed or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received a trastuzumab-based regimen.
• In November 2021, in order to treat advanced colorectal and stomach cancer, “Natco Pharma” has introduced a brand-new fixed-dose combination of trifluridine and tipiracil. The business has introduced “Tipanat” as the brand name in a bottle-packed pack of 20 pills. 

The key players operating the Gastric Cancer Treatment Market includes Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck KGaA, Novartis International AG, Otsuka Holdings Co. Ltd., Bristol-Myers Squibb Company, Pfizer, Inc., Celltrion, Inc.

• Biogen, Inc*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Eli Lilly and Company
• F.Hoffman-La Roche Ltd
• GlaxoSmithKline Plc
• Merck KGaA
• Novartis International AG
• Otsuka Holdings Co. Ltd
• Bristol-Myers Squibb Company
• Pfizer, Inc
• Celltrion, Inc

“*” marked represents similar segmentation in other categories in the respective section

Research Objective and Assumption

• Preface
• Research Objectives
• Study Scope
• Years Considered for the study
• Assumptions
• Abbreviations

Research Methodology

• Research data
• Primary Data
  • Primary Interviews
  • Primary Breakdown
  • Key data from Primary Sources
  • Key Thickness Insights
• Secondary Data
  • Major Secondary Sources
  • Secondary Sources
• Market Estimation
• Top-Down Approach
  • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
• Bottom-Up Approach
  • Approach for estimating market share by Bottom-up Analysis (Demand Side)
• Market Breakdown and Data Triangulation
• Research Assumptions

Market Preview

• Executive Summary
• Key Findings—Global Outlook for medical carts Strategies
  • Key Questions this Study will Answer
  • Market Snippet, By Treatment
  • Market Snippet, By End User
  • Market Snippet, By Region
• Opportunity Map Analysis
• Executive Summary—3 Big Predictions

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restrains
  • Market Opportunities
  • Market Trends
• DR Impact Analysis
• PEST Analysis
• Porter’s Five Forces Analysis
• Opportunity Orbit
• Market Investment Feasibility Index
• Macroeconomic Factor Analysis

Gastric Cancer Treatment Market, By Treatment, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Surgery
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Chemo Therapy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Adjuvant Chemotherapy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Targeted Drugs Therapy (Sunitinib (Sutent
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Trastuzumab (Herceptin)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Imatinib (Gleevec)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Radiation Therapy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Gastric Cancer Treatment Market, By End User, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Hospitals 
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Clinics
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Specialized Cancer Treatment Centers
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Ambulatory Surgical Centers
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Gastric Cancer Treatment Market, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By By End User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By By End User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • France
    • Germany
    • Russia
    • Italy
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By By End User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By By End User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• Brazil
• Mexico
• Rest of Latin America

 

• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By By End User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• GCC
• Israel
• South Africa
• Rest of Middle East

Competitive Landscape

• Heat Map Analysis
• Market Presence and Specificity Analysis

Company Profiles

• Biogen, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Eli Lilly and Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• GlaxoSmithKline plc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Merck KGaA
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis International AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Otsuka Holdings Co. Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bristol-Myers Squibb Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Pfizer, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Celltrion, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

The Last Word

• Future Impact
• About Us
• Contact